We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current 0J2O market cap is 2.41B. The company's latest EPS is USD 2.1317 and P/E is 22.79.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 195.99M | 267.59M | 443.31M | 660.12M | 829.25M |
| Operating Income | -67.61M | 144.26M | 275.9M | 267.53M | 337.57M |
| Net Income | -72.24M | 129.09M | 402.71M | 202.13M | 281.59M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 565.87M | 579.92M | 1.1B | 1.84B | 1.73B |
| Total Liabilities | 474.11M | 428.88M | 907.48M | 1.67B | 1.65B |
| Total Equity | 91.77M | 151.05M | 196.95M | 169.8M | 83.81M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -85.42M | 55.45M | 299.44M | 240.11M | 388.57M |
| Investing | -5.55M | 78.35M | -406.29M | -487.01M | -96.91M |
| Financing | 153.22M | -106.28M | 77.87M | 362.37M | -407.99M |
| Market Cap | 2.41B |
| Price to Earnings Ratio | 22.79 |
| Price to Sales Ratio | 7.74 |
| Price to Cash Ratio | 54.22 |
| Price to Book Ratio | 76.59 |
| Dividend Yield | - |
| Shares Outstanding | 132.1M |
| Average Volume (1 week) | 1.12k |
| Average Volume (1 Month) | 2.74k |
| 52 Week Change | 0.00% |
| 52 Week High | 18.26 |
| 52 Week Low | 18.26 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Halozyme Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.halozyme.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
